Media Center

Latest Press Releases

10th April 2025

Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO

29th March 2025

Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25

17th March 2025

Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25)

30th August 2024

Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024

8th April 2024

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

25th March 2024

Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)

Latest Publications and Presentations

29th March 2025

ACC.25 Effects of Ninerafaxstat on myocardial energetics, exercise capacity, and cardiac function in heart failure with preserved ejection fraction, Type 2 Diabetes and Obesity- a Phase 2a clinical trial

31st August 2024

ESC Congress 2024 IMPROVE-ISCHEMIA Presentation

8th April 2024

ACC.24 Late-Breaking IMPROVE-HCM Presentation

You Are About to Leave Imbria Pharmaceuticals

The appearance of external hyperlinks does not constitute endorsement by Imbria Pharmaceuticals of the linked websites, or the information, products or services contained therein.

URL: